Solid Earnings Reflect Vikas Lifecare's (NSE:VIKASLIFE) Strength As A Business
Even though Vikas Lifecare Limited's (NSE:VIKASLIFE) recent earnings release was robust, the market didn't seem to notice. Investors are probably missing some underlying factors which are encouraging for the future of the company.
Examining Cashflow Against Vikas Lifecare's Earnings
One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.
Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.
Vikas Lifecare has an accrual ratio of -0.46 for the year to March 2026. That indicates that its free cash flow quite significantly exceeded its statutory profit. In fact, it had free cash flow of ₹3.1b in the last year, which was a lot more than its statutory profit of ₹184.1m. Notably, Vikas Lifecare had negative free cash flow last year, so the ₹3.1b it produced this year was a welcome improvement. However, that's not all there is to consider. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio.
View our latest analysis for Vikas Lifecare
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Vikas Lifecare.
The Impact Of Unusual Items On Profit
Vikas Lifecare's profit was reduced by unusual items worth ₹96m in the last twelve months, and this helped it produce high cash conversion, as reflected by its unusual items. This is what you'd expect to see where a company has a non-cash charge reducing paper profits. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Vikas Lifecare to produce a higher profit next year, all else being equal.
Our Take On Vikas Lifecare's Profit Performance
In conclusion, both Vikas Lifecare's accrual ratio and its unusual items suggest that its statutory earnings are probably reasonably conservative. After considering all this, we reckon Vikas Lifecare's statutory profit probably understates its earnings potential! So while earnings quality is important, it's equally important to consider the risks facing Vikas Lifecare at this point in time. Every company has risks, and we've spotted 2 warning signs for Vikas Lifecare you should know about.
Our examination of Vikas Lifecare has focussed on certain factors that can make its earnings look better than they are. And it has passed with flying colours. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.